The platform leverages state-of-the-art generative artificial intelligence (AI) to design selective inhibitors of the Sec61/translocon molecular complex for blocking and degrading disease-causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback